Twist Bioscience sees Q2 revenue $91M-$93M, consensus $91.11M

Sees Q2 adjusted EBITDA loss $16M. Leproust continued, “As we move through 2025, we are pursuing multiple growth vectors that we believe will help us to achieve adjusted EBITDA breakeven and then build on our foundation to drive sustainable growth in the years to come. Importantly, we expect to exit the fourth quarter of fiscal 2025 with gross margin over 50%.”